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Abstract
Objective
To determine the association of serum neurofilament light chain (NfL) with functional deterioration and
brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD).
Methods
Blood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive
impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed
for the diagnostic potential in relation to functional assessment (Clinical Dementia Rating Scale Sum of
Boxes [CDR-SOB], frontotemporal lobar degeneration–related CDR-SOB, Mini-Mental State Examina-
tion [MMSE]) and brain volumetry.
Results
At baseline, serumNfL level correlated with CSFNfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666, p =
0.0003). Highest serum levels were observed in bvFTD (p <0 0.0001 vs Con and MCI, p = 0.0078 vs AD,
respectively). Discrimination of bvFTD from Con/MCI/AD was possible with 91%/74%/74% sensitivity
and 79%/74%/58% specificity. At follow-up, serum NfL increased in bvFTD and AD (p = 0.0039 and p =
0.0006, respectively). At baseline and follow-up,NfL correlatedwith functional scores of patients with bvFTD
(e.g., CDR-SOB [baseline] r = 0.4157, p = 0.0006; [follow-up] r = 0.5629, p < 0.0001) and with atrophy in
the gray and white matter of many brain regions including frontal and subcortical areas (e.g., frontal lobe: r =
−0.5857, p < 0.0001; 95% confidence interval −0.7415 to −0.3701). For patients with AD/MCI, NfL
correlated with the functional performance as well (e.g., CDR-SOB [baseline] r= 0.6624, p< 0.0001; [follow-
up] r = 0.5659, p = 0.0003) but not with regional brain volumes.
Conclusions
As serum NfL correlates with functional impairment and brain atrophy in bvFTD at different disease
stages, we propose it as marker of disease severity, paving the way for its future use as outcome measure
for clinical trials.
Classification of evidence
This study provides Class III evidence that for patients with cognitive problems, serumNfL concentration
discriminates bvFTD from other forms of dementia.
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Frontotemporal dementia (FTD), a form of dementia af-
fecting people under the age of 65 years,1 represents a clini-
cally and neuropathologically heterogeneous group of
diseases within the spectrum of frontotemporal lobar degen-
erations (FTLD). The most frequent form is behavioral var-
iant FTD (bvFTD), which is characterized by progressive
changes in personality and behavior, often expressed as apathy
and disinhibition. Cognitive deficits can be seen as deficits of
executive functions while memory is largely preserved. Neu-
roimaging of frontal brain region atrophy, starting in the
frontoinsular cortices and further regions of the medial par-
alimbic network, is included in the revised diagnostic criteria
for probable bvFTD2,3 and has been demonstrated in compre-
hensive imaging meta-analyses.4,5 At the neuropathologic level,
90% of bvFTD cases are characterized by tau or TDP-43 pa-
thology in equal shares, and about 10% show FUS pathology.6,7
At present, in bvFTD only behavioral symptoms are treated
pharmacologically, e.g., some patients benefit from selective
serotonin reuptake inhibitors,8 but there is no medication
available targeting the underlying pathogenesis. Our knowl-
edge about pathomechanisms, however, has substantially
increased within the last decade, giving hope that
neuroprotective etiology-specific treatment will be available in
the foreseeable future. When available, it is important to have
tools, such as neurochemical biomarkers, to monitor disease
progression and therapy effects in patients.
Neurofilament light chain (NfL) is a component of the neu-
ronal cytoskeleton released into CSF and blood upon neu-
rodegeneration. Increased CSF levels have been reported for
amyotrophic lateral sclerosis (ALS) and some of the FTLD
spectrum diseases, which pathophysiologically are closely
related, but also for other diseases, e.g., Alzheimer disease
(AD), multiple sclerosis, or traumatic brain injury.9–13
The recent development of a sensitive electrochemiluminescence
immunoassay and in particular the establishment of an ul-
trasensitive single-molecule immunoassay for the measure-
ment of NfL now enables us to reliably quantify NfL in
serum,14,15 resulting in the first reports on increased levels
in neurodegenerative diseases, including those of the
ALS–FTLD spectrum, in part correlating with disease se-
verity and progression.12,16–24
In the present study, we aimed to determine the potential of
blood NfL levels as a measure to objectively monitor disease
progression in bvFTD. We considered subgroups clinically
diagnosed with possible bvFTD and probable bvFTD since
clinical trials most likely will initially include the latter group,
and compared our results with those from patients with AD
and patients with mild cognitive impairment (MCI), as well as
healthy controls, as reference groups to examine the speci-
ficity of blood NfL.
Methods
The primary research question was the following: Do serum
NfL levels discriminate bvFTD from AD, MCI, and controls
(Class III level of evidence)?
Standard protocol approvals, registrations,
and patient consents
The study was conducted according to the principles
expressed in the Declaration of Helsinki. Collection and
analysis of samples were approved by the local ethics com-
mittees of Departments of Neurology and Psychiatry
participating in the German FTLD Consortium, a quality-
controlled, monitored, multicenter initiative (Ulm approval
number 20/10).25 All patients or their legal relatives in case of
severe dementia gave written informed consent to their par-
ticipation in the study.
Participants
A total of 132 patients were included in this prospective study.
Patients for whom at least one in-depth follow-up examina-
tion with serum sampling after a regular interval of 1 year (±3
months) was available were included in our study. De-
mographic and disease data are given in tables 1 and 2.
The bvFTD group consisted of 74 patients including 27
possible and 38 probable bvFTD cases diagnosed according
to international diagnostic criteria.2,3 Genetic screening of 67
patients with bvFTD for C9orf72 repeat expansion revealed 7
carriers. Analysis ofMAPT and GRN in 18 patients revealed 1
carrier of the MAPT:c.1008 G>C (p.Gln336His) mutation
and 1 carrier of the GRN: c.349+1G>C mutation. The 9
patients carrying mutations were categorized as definite
bvFTD. Disease duration at baseline, defined as interval be-
tween the date of first symptoms reported by the patient or
caregiver and the date of blood/CSF sampling, ranged from 4
months to 13.4 years. CSF samples were taken at baseline
from 37 patients with bvFTD (15 possible, 17 probable, and 5
definite) and for none of these was a biomarker pattern typical
for AD (β-amyloid 1–42 [Aβ42] <550 pg/mL, tau >450 pg/
Glossary
Aβ42 = β-amyloid 1–42; AD = Alzheimer disease; ALS = amyotrophic lateral sclerosis; AUC = area under the curve; bvFTD =
behavioral variant frontotemporal dementia; CDR-SOB = Clinical Dementia Rating scale Sum of Boxes; CI = confidence
interval; FTD = frontotemporal dementia; FTLD = frontotemporal lobar degeneration; ICV = intracranial volume;MCI =mild
cognitive impairment;MMSE =Mini-Mental State Examination;NfL = neurofilament light chain; p-tau = phosphorylated tau;
pNfH = phosphorylated neurofilament heavy chain; ROC = receiver operating characteristic; v1 = visit 1; v2 = visit 2.
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mL, phosphorylated tau [p-tau] >61 pg/mL) determined. For
24 patients with bvFTD (2 definite, 10 probable, and 12
possible cases), at least a second follow-up examination (visit
3) was available.
The reference cohort consisted of 26 patients with AD,26 17
patients with MCI,27 and 15 controls without neurologic disease
and without acute or chronic inflammation of the brain. Genetic
assessment for C9orf72 of 19 patients with AD, 11 patients with
MCI, and 8 controls, and forMAPT andGRN of 7 patients with
AD, 1 patient with MCI, and 2 controls, revealed no carrier of
repeat expansion ormutation, respectively. CSF samples from16
patients with AD and 9 patients with MCI could be taken at first
examination. Out of the 16 AD samples, 8 had a typical CSF AD
core marker pattern. A total of 26 patients with AD, 17 patients
with MCI, and 14 controls had at least a second follow-up
examination. No patient of the MCI group converted to AD or
any other dementia within the study interval.
Table 1 Demographic characteristics, functional performance, brain volumetry, and serum neurofilament light chain
(NfL) of the study subgroups at baseline
bvFTD AD MCI Controls p Value
No. 74 26 17 15
F/M 30/44 11/15 4/13 9/6
Age, y, mean (SD) 63.7 (9.2) 67 (8.1) 63.1 (9.3) 64.8 (11.3) 0.3540
Disease duration, y, mean (SD) 3.9 (3.4) 3.4 (2.1) 3.6 (3.2) NA 0.8356
Serum NfL, pg/mL, mean (SD) 49.0 (35.2) 32.3 (15.8) 16.6 (8.1) 21.7 (20.6) <0.0001a
No. 69 26 17 15
MMSE, mean (SD) 24.2 (5.2) 21.6 (6.0) 27.9 (1.9) 29 (0.8) <0.0001b
No. 64 22 16 15
CDR-SOB, mean (SD) 6.5 (4.6) 5.1 (2.4) 0.75 (0.7) 0.1 (0.2) <0.0001c
FTLD-CDR-SOB, mean (SD) 8.8 (5.7) 6.6 (3.3) 0.9 (0.9) 0.1 (0.2) <0.0001c
No. 54 21 16 12
Cerebrum, mL, mean (SD) 818 (63.9) 803 (44.5) 877 (51) 873 (69) 0.0001d
Frontal lobe, mL, mean (SD) 257 (33.3) 265 (18.9) 292 (19.8) 292 (16.4) <0.0001e
Temporal lobe, mL, mean (SD) 161 (20.0) 152 (14.0) 176 (11,4) 177 (9.3) 0.0001f
No. 38 16 9
CSF NfL, pg/mL, mean (SD) 2,948 (2,630) 1,595 (1,005) 1,110 (691) 0.0036g
CSF pNfH, pg/mL, mean (SD) 446 (248) 340 (145) 262 (128) 0.0185h
CSF tau, pg/mL, mean (SD) 461 (413) 659 (268) 299 (144) 0.0009i
CSF p-tau, pg/mL, mean (SD) 60.6 (35.8) 78.1 (34.0) 50.0 (25,9) 0.0365j
CSF Aβ42, pg/mL, mean (SD) 941 (375) 545 (226) 781 (291) 0.0007k
Aβ42-positive samples,l % 21.0 68.8 33.3
Abbreviations: Aβ42 = β-amyloid 1–42; AD = Alzheimer disease; bvFTD = behavioral variant frontotemporal dementia; CDR-SOB = Clinical Dementia Rating
Sum of Boxes; FTLD = frontotemporal lobar degeneration; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; NA = not applicable; p-
tau = phosphorylated tau; pNfH = phosphorylated neurofilament heavy chain.
The Kruskal-Wallis test was applied to all study subgroups. For statistical differences of CSF measures, the control group was omitted because of the low
patient number tested.
a bvFTD vs AD p < 0.01, vs MCI p < 0.001, vs controls p < 0.001; AD vs MCI p < 0.05.
b bvFTD vs AD p < 0.05, vs controls p < 0.01; AD vs MCI p < 0.001, AD vs controls p < 0.001.
c bvFTD vs MCI p < 0.001, vs controls p < 0.0001; AD vs MCI p < 0.001, vs controls p < 0.001.
d bvFTD vs MCI p < 0.05, vs controls p < 0.01; AD vs MCI p < 0.01, vs controls p < 0.001.
e bvFTD vs MCI p < 0.05, vs controls p < 0.001; AD vs controls p < 0.05.
f AD vs MCI p < 0.001, vs controls p < 0.01.
g bvFTD vs MCI p < 0.01.
h bvFTD vs MCI p < 0.05.
i bvFTD vs AD p < 0.01; AD vs MCI p < 0.01.
j Post hoc test not significant.
k bvFTD vs AD p < 0.001.
l Aβ42 < 550 pg/mL.
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Assessment of all patients at baseline and follow-up inves-
tigations included a standardized clinical–neurologic exami-
nation, MRI, and functional characterization by means of
global rating scales (Mini-Mental State Examination
[MMSE], Clinical Dementia Rating scale Sum of Boxes
[CDR-SOB], and FTLD-specific CDR-SOB).
MRI and volumetric analyses
Datasets from baseline and at least one follow-up visit were
available for 33 patients with bvFTD (12 possible, 17 prob-
able, and 4 definite bvFTD), 13 patients with AD, 13 patients
with MCI, and 12 control participants. 3TMRI data including
3DT1magnetization-prepared rapid gradient echo sequences
were recorded according to standardized protocols. The
volumes of different brain regions were determined as de-
scribed elsewhere.20,28,29
Laboratory markers
Serum was extracted from blood, aliquoted, and stored within 2
hours at −80°C until analysis. CSF was obtained by lumbar
puncture and processed likewise. All analyses were performed in
a blinded manner. CSF examination included measurement of
NfL (IBL, Hamburg, Germany), phosphorylated Nf heavy
chain (pNfH) (Biovendor, Heidelberg, Germany), tau and
p-tau, and Aβ42 (Fujirebio, Hanover, Germany). Serum NfL
was measured by single-molecule assay (Quanterix, Lexington,
MA). Intra-assay and interassay variability was determined by
measuring the same 3 samples as triplicates on 3 separate plates:
intra-assay: <6.4% (mean 4.1%), interassay: <15.9% (mean
10.5%). Stability was ensured for up to 4 freeze-thaw cycles and
up to 48 hours storage at room temperature (variability <11%).
Statistical analysis
Nonparametric tests were applied in all analyses. Two groups
of measures were analyzed for significant differences by
Mann-Whitney test. Three or more groups were analyzed by
Kruskal-Wallis test, followed by Dunn post hoc test in case of
significant results. Correlation of follow-up serum NfL levels
was analyzed by Wilcoxon matched pairs test. p < 0.05 Was
regarded as significant.
The optimal cutoff level for dichotomizing values was selected
as the situation maximizing the Youden index. The receiver
operating characteristics (ROC) curve is used for a graphic
visualization of the effect of the variation in the cutoff values.
All results of atlas-based volumetry were corrected (by division)
for individual intracranial volume (ICV) of each participant and
then normalized to an ICV of 1,400 mL, which corresponds to
the approximate average ICV of healthy adult controls. To
compare the progression of brain atrophy, either absolute dif-
ferences in the ICV-normalized volumes were used or volumes
measured at follow-up were normalized to the volumes at
baseline and expressed as percentage volume change.
Table 2 Serum neurofilament light chain (NfL) at follow-up andmeasures of disease progression in the study subgroups
bvFTD AD MCI Controls p Value
Time between v1 and v2, mo, mean (SD) 12.9 (2.3) 13.1 (2.2) 12.0 (2.5) 13.1 (2.7) 0.5535
Serum NfL at v2, pg/mL, mean (SD) 56.9 (40.3) 38.1 (20.6) 21.5 (18.9) 17 (7.3) <0.0001a
Change in serum NfL, pg/mL, mean (SD) 8 (26.9) 5.8 (7.9) 4.9 (15.4) −3.4 (21) 0.2789
No. 64 26 17 14
Change in MMSE, mean (SD) −4.4 (6) −4.5 (4.5) −0.2 (2.2) −0.4 (1.7) 0.0002b
No. 61 19 15 13
Change in CDR-SOB, mean (SD) 2.3 (3.6) 1.8 (2.6) 0.3 (1.1) −0.04 (0.2) 0.0003c
No. 60 19 15 13
Change in FTLD-CDR-SOB, mean (SD) 2.9 (4,6) 2.4 (3) 0.5 (1.5) −0.04 (0.2) 0.0004d
No. 33 13 13 12
Cerebrum atrophy, %, mean (SD) −1.8 (2.2) −1.9 (3.4) −0.3 (2.9) −0.07 (1.4) 0.0418e
Frontal lobe atrophy, %, mean (SD) −3 (4.8) −2.5 (4.8) −0.3 (2.8) 0.3 (1.8) 0.0316e
Temporal lobe atrophy, %, mean (SD) −2.2 (3) −1.3 (3.1) 0.04 (3.5) −0.7 (2) 0.1633
Abbreviations: AD =Alzheimer disease; bvFTD = behavioral variant frontotemporal dementia; CDR-SOB = Clinical Dementia Rating scale Sumof Boxes; FTLD =
frontotemporal lobar degeneration; MCI = mild cognitive impairment; MMSE = Mini-Mental-State Examination; v1 = visit 1; v2 = visit 2.
a bvFTD vs MCI p < 0.001, vs controls p < 0.001; AD vs MCI p < 0.05, vs controls p < 0.01.
b bvFTD vs MCI p < 0 0.01, vs controls p < 0.05; AD vs MCI p < 0.01, vs controls p < 0.01.
c bvFTD vs MCI p < 0.05, vs controls p < 0.01; AD vs controls p < 0.05.
d bvFTD vs MCI p < 0.05, vs controls p < 0.05; AD vs MCI p < 0.05, vs controls p < 0.05.
e Post hoc test not significant.
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To determine correlation of measures, Spearman rank co-
efficient was applied considering p < 0.05 significant. For the
analysis of correlation of serum NfL with 201 regional brain
volumes, Bonferroni correction for multiple comparisons was
applied and p < 0.0025 was considered significant.
All analyses were performed using GraphPad (La Jolla, CA)
Prism 5.0 software.
Data availability
Any data not published within the article will be shared in
pseudonymized form by request from any qualified in-
vestigator for purposes of replicating procedures.
Results
Description of the cohort at
baseline examination
Demographic characteristics, functional performance, brain
volumetric measures, and CSF biomarker concentrations for
the study groups bvFTD, AD, MCI, and controls at baseline
are given in table 1.
Measures did not differ comparing the bvFTD subgroups
(possible bvFTD, probable bvFTD, definite bvFTD); there-
fore all analyses were applied to a single group bvFTD.
The bvFTD, AD,MCI, and controls groups did not differ with
respect to age (p = 0.345) and the disease duration was
comparable in the diseased study groups (p = 0.8356).
Functional constraints quantified by means of MMSE were
more severe in the AD group (p < 0.05 compared to bvFTD, p
< 0.001 compared to MCI and controls, respectively) than in
the bvFTD group (p < 0.01 compared to controls, not sig-
nificant vs MCI). Assessment by CDR-SOB or FTLD-CDR-
SOB revealed a more severe impairment for bvFTD or AD vs
MCI or controls (p < 0.001).
Themean volume of the cerebrumwas different in the groups,
with lower values in the bvFTD and AD groups compared to
MCI and controls (figure 1A). The differences were more
pronounced when looking at regions typically affected in
bvFTD and AD: comparing the diseased groups, the frontal
lobe volume was lowest in bvFTD (not significant compared
to AD, p < 0.001 compared to MCI) and the hippocampal
volume was lowest in AD (p < 0.05 vs bvFTD and p < 0.001 vs
MCI). Temporal lobe volumes were smallest in AD (p <
0.001 vs MCI and p < 0.01 vs controls), but not smaller if
compared to bvFTD (table 1). All baseline regional brain
volumes for the study groups are given in table e-1.
In CSF samples (bvFTD, AD, and MCI), neurofilaments
(NfL and pNfH) and the AD biomarker panel (tau, p-tau,
Aβ42) were measured (table 1). Neurofilaments were highest
in the bvFTD group (p < 0.05 vs AD, p < 0.01 vs MCI),
patients with AD showed intermediate levels, and patients
with MCI had the lowest levels (AD vs MCI not significant).
For tau and p-tau, the levels were highest for AD and similar
for bvFTD and controls (tau: p < 0.01 for bvFTD vs AD and p
< 0.001 for AD vs MCI; p-tau: p = 0.0365, not significant in
the post hoc test). A marked reduction of Aβ42 was seen for
patients with AD and in patients with MCI Aβ42 also tended
to have decreased levels, while the bvFTD group was char-
acterized by a high variability of Aβ42 with a mean value in the
range of healthy individuals (bvFTD vs AD p < 0.001). A
considerable number of patients in our AD group had normal
Aβ42 (31%), normal tau (25%), or normal p-tau levels (31%).
Among those with normal Aβ42, 2 patients had tau or p-tau
below the cutoff. In the bvFTD group, 21% of patients had
reduced Aβ42, and 7 of these also had increased p-tau or tau
levels.
The serum NfL level was highest for patients with bvFTD,
followed by AD, MCI, and controls (figure 1B).
Baseline serum NfL of patients with bvFTD,
diagnostic performance, and correlation with
disease measures
Based on the serum NfL level, patients with bvFTD could be
differentiated from controls with 91% sensitivity (95%
confidence interval [CI] 81%–96%) and 79% specificity
(95% CI 49%–95%) at a cutoff of 19.5 pg/mL. For the
discrimination of bvFTD from AD and MCI, the highest
index was calculated for a cutoff of 29.5 pg/mL, yielding 74%
sensitivity (95% CI 63%–84%) with 58% and 74% specific-
ity, respectively (figure 1C).
Serum NfL correlated for the bvFTD group with CSF NfL
(r = 0.706, p < 0.0001) and CSF tau (r = 0.4979, p = 0.0015)
(figure 1D) but not with CSF pNfH (r = 0.2689, p =
0.1026), p-tau (r = 0.1897, p = 0.2409), or Aβ42 (r =
−0.1136, p = 0.4852). While there was no correlation of
serum NfL with the patient’s age or disease duration (table
e-2), it correlated with results of functional assessment
(CDR-SOB: r = 0.4157, p = 0.0006, 95% CI 0.1821 to
0.6050; MMSE: r = −0.4114, p = 0.0004, 95% CI −0.5952 to
−0.1866; FTDL-CDR-SOB: r = 0.4175, p = 0.0006, 95% CI
0.1841 to 0.6464) (figure 1D).
The volumes of a number of brain regions correlated with
the level of serum NfL. Results that remained significant
after Bonferroni correction for multiple comparisons were
obtained for the frontal lobe (figure 1E) and multiple sub-
regions of it, while regional volumes of the temporal lobe
showed a weaker association with serum NfL, and parietal or
occipital regions did not correlate with NfL. A correlation
with serum NfL was observed for striatal and limbic system
regions (figure 1,G and H) and also for white matter vol-
umes (figure 1I). A summary of correlation analysis results
for serum NfL at baseline with demographic, disease, and
CSF measures and with regional brain volumes is given in
table e-2.
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Baseline serum NfL of patients with AD and
patients with MCI and correlation with
disease measures
In contrast to bvFTD, in the AD group, serum NfL correlated
with the patient’s age at examination and the age at reported
symptom onset (age at baseline: r = 0.6857, p = 0.0006, 95%
CI 0.3488 to 0.8657; age at onset: r = 0.7771, p < 0.0001, 95%
CI 0.4993 to 0.9100). Serum NfL correlated with the CDR-
SOB (r = 0.4402, p = 0.04, 95% CI 0.0095 to 0.7332) and the
FTLD-CDR-SOB score (r = 0.5297, p = 0.0112, 95% CI
0.1261 to 0.7829), but not with the MMSE score (r =
−0.3242, p = 0.161, 95% CI −0.694 to 0.0843) for patients
with AD. In the MCI group, scores did not correlate with
serum NfL.
Some regional brain volumes of the AD and the MCI group
correlated with the serum NfL level, with the association
failing to remain after correction for multiple comparisons
(table e-2).
Looking at CSF markers, there was no correlation to serum
NfL in the AD or MCI group. Defining AD and MCI patients
together as neurologic control group, serum NfL correlated
with CSF NfL (r = 0.6662, p = 0.003, 95% CI 0.357 to
0.8438).
Serum NfL level at follow-up examination
Characteristics of disease progression at follow-up in the
bvFTD and the control groups are given in table 2.
Figure 1 Serumneurofilament light chain (NfL) levels and correlationwith functional scores and brain volumetric results at
baseline examination
(A) Intracranial volume–normalized cerebrum volumes and (B) serum NfL levels of the diagnostic groups. Boxes show 25th and 75th percentile
values with median values, whiskers indicate 5th and 95th percentile values, asterisks indicate significant differences determined by post hoc
testing after Kruskal-Wallis analysis (*p < 0.05, **p < 0.01, ***p < 0.001). (C) Receiver operating characteristic curves for the discrimination of
behavioral variant frontotemporal dementia (bvFTD) from Alzheimer disease (AD), mild cognitive impairment (MCI), or controls. (D) Correlation and
linear regression of log-transformed concentrations of serum NfL with CSF NfL (filled circles) and CSF tau (open circles) for bvFTD. (E) Correlation of
serum NfL with frontotemporal lobar degeneration Clinical Dementia Rating scale Sum of Boxes (FTLD-CDR-SOB) score for bvFTD (left y axis, red)
and with Mini-Mental State Examination (MMSE) for AD (right y axis, blue). (F–I) Correlation between serum NfL and volumes of the frontal lobe,
striatum, right amygdala, and white matter of the frontal lobe. Red indicates bvFTD data, blue indicates AD. AUC = area under the curve; CI =
confidence interval.
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In line with the results at baseline examination (visit 1 [v1]),
patients with bvFTD had the highest serum NfL level,
for patients with AD increased levels were determined again,
and patients with MCI and controls still had low levels at
second follow-up examination (visit 2 [v2]) (figure 2A).
Compared to v1, patients with bvFTD and patients with AD
had increased serumNfL concentrations at v2 (Wilcoxon test:
p = 0.0039 and p = 0.0006, respectively), whereas levels stayed
low for patients with MCI (p = 0.1406) and control patients
(p = 0.3461).
As the individual change of serum NfL from v1 to v2 varied
substantially for patients with bvFTD, we examined whether
there was a difference in the subgroup of definite/probable vs
possible bvFTD cases. We found that in both subgroups,
serum NfL levels increased on average with a significant result
for the genetic/probable bvFTD subgroup (figure 2, B
and C).
Correlation of serum NfL with functional
scores and brain atrophy at follow-up
For bvFTD but not AD, the serum NfL level still correlated
with the MMSE score (figure 2D), FTLD-CDR-SOB score
(figure 2E), and CDR-SOB score (r = 0.5076, 95% CI 0.2960
to 0.6717, p < 0.0001), as well as with volumes of several brain
regions, including, e.g., the frontal lobe (figure 2F). Overall,
the results were similar to those obtained for bvFTD and also
for AD at baseline. A summary of Spearman correlation
analysis at v2 is given in table e-3.
Subgroup analysis of possible and genetic/probable bvFTD
for correlation of serum NfL with psychometric and mor-
phometric measurements yielded no difference for the clinical
groups and results were similar to those obtained for all
bvFTD cases (data not shown).
No correlation was found for the change in NfL levels with the
change in functional scores or the change in the degree of
Figure 2 Serumneurofilament light chain (NfL) at follow-up visits (visit 1 [v1]–visit 3 [v3]) and correlationwith functional and
morphologic measures
(A) Change ofmean serumNfL concentration frombaseline examination (v1) to follow-up 2 years later (v3). Bars represent the 95% confidence interval (CI). (B,
C) Individual changes in serum NfL concentrations from baseline (v1) to follow-up 1 year later (v2) with Wilcoxon test results for patients with behavioral
variant frontotemporal dementia (bvFTD) clinically diagnosed with possible bvFTD (B) and definite/probable bvFTD cases (C), respectively. (D, E) Correlation
and linear regression for serumNfL and functional scores for bvFTD (red) and Alzheimer disease (AD) (blue) at follow-up after 1 year (v2). In (F), the correlation
and linear regression of serum NfL and frontal lobe volumes at follow-up after 1 year (v2) for bvFTD (red) and AD (blue) are shown. (G) Relation between the
change in serumNfL and the frontal lobe atrophy frombaseline (v1) to follow-up after 1 year (v2) for bvFTD (red) andAD (blue). CDR=Clinical Dementia Rating;
FTLD = frontotemporal lobar degeneration; MCI = mild cognitive impairment.
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Table 3 Analysis of behavioral variant frontotemporal dementia (bvFTD) and Alzheimer disease (AD) subgroups selected
based on CSF biomarker levels
Aβ42 consistent with non-AD vs AD Aβ42 and tau or p-tau consistent with non-AD vs AD
bvFTD (30) AD (11) bvFTD (31) AD (14)
Serum NfL at v1, mean
(SD)
45.2 (25) 25 (9.9) 64.6 (9.6) 25.3 (9.5)
bvFTD vs AD (v1) p = 0.0038 p = 0.0015
Cutoff, pg/mL 33.0 34.3
ROC-AUC 0.8 0.8
Sensitivity % 90 93
Specificity % 67 61
Correlation at v1 of serumNfL
with bvFTD
Correlation at v1 of serum
NfL with AD
Correlation at v1 of serumNfL
with bvFTD
Correlation at v1 of serum
NfL with AD
MMSE r = −0.4445 r = −0.1785 r = −0.4425 r = −0.1191
p = 0.0156 p = 0.5995 p = 0.0143 p = 0.6852
CDR-SOB r = 0.3404 r = 0.4771 r = 0.3321 r = 0.4747
p = 0.0823 p = 0.1632 p = 0.0843 p = 0.1401
FTLD-CDR-SOB r = 0.3539 r = 0.4878 r = 03527 r = 0.4612
p = 0.0702 p = 0.1526 p = 0.0656 p = 0.1534
Cerebrum r = −0.5270 r = 0.4333 r = −0.5231 r = 0.2727
p = 0.0082 p = 0.2440 p = 0.0073 p = 0.4171
Frontal lobe r = −0.4557 r = 0.0167 r = −0.4515 r = −0.0182
p = 0.0252 p = 0.9661 p = 0.0235 p = 0.9577
Temporal lobe r = −0.5226 r = 0.1500 r = −0.5169 r = −0.2636
p = 0.0088 p = 0.7001 p = 0.0081 p = 0.4334
Hippocampus r = −0.4209 r = 0.2333 r = −0.4262 r = −0.2455
p = 0.0406 p = 0.5457 p = 0.0337 p = 0.4669
CSF NfL r = 0.7325 r = 0.2636 r = 0.7197 r = 0.3451
p < 0.0001 p = 0.4334 p < 0.0001 p = 0.2269
CSF pNfH r = 0.2884 r = 0.00 r = 0.2801 r = −0.1123
p = 0.1222 p = 1.0000 p = 0.1270 p = 0.7022
CSF Aβ42 r = −0.2091 r = −0.0909 r = −0.1988 r = −0.0022
p = 0.2674 p = 0.7904 p = 0.2836 p = 0.9941
CSF tau r = 0.4874 r = 0.5818 r = 0.4748 r = 0.5209
p = 0.0063 p = 0.0604 p = 0.0070 p = 0.0562
CSF p-tau r = 0.1994 r = 0.3364 r = 0.1906 r = 0.3670
p = 0.2908 p = 0.3118 p = 0.3044 p = 0.1967
Wilcoxon test serum
NfL v1→v2
p = 0.0002 p = 0.0087 p = 0.0002 p = 0.0021
Serum NfL (v2), mean
(SD)
64 (42.3) 30.5 (13) 63.6 (42.6) 31.7 (12.6)
bvFTD vs AD (v2) p = 0.0053 p = 0.0041
Cutoff 41.3 45.7
Continued
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regional brain atrophy, when looking at absolute or normal-
ized concentration/volume changes (as example, the frontal
lobe is shown in figure 2G).
Serum NfL in patients with genetic bvFTD with
GRN, MAPT, or C9orf72 mutation/expansion
Looking at the demographic characteristics, functional scores,
regional brain volumes, and CSFmarker levels, no remarkable
differences could be observed between the identified genetic
cases and patients tested negative or patients not tested. The
patient with novel splice site mutation inGRN had a relatively
high serum NfL level that was further increased at follow-up
(v1: 134 pg/mL, v2: 149 pg/mL) and also the patient with
MAPT mutation, who had an intermediate NfL level (55 pg/
mL), showed increasing concentrations over time (v2: 77 pg/
mL, visit 3: 98 pg/mL). For the 7 patients withC9orf72 repeat
expansion, mean NfL serum level was in the range of all
bvFTD (v1: 45.6 pg/mL) and increased on average (v2: 50.4
pg/mL).
SerumNfL in patients with bvFTD and patients
with AD selected on the basis of CSF AD
core biomarkers
Because of discrepancies between clinical diagnosis of bvFTD
and AD on the one hand, and levels of the CSF AD core
biomarkers on the other hand, we performed additional
analyses with a group definition based on CSF biomarkers
(table 3). By excluding patients with bvFTD with decreased
Aβ42 and patients with AD with normal Aβ42, the difference
between serum NfL levels in the 2 diagnosis groups slightly
increased and ROC analysis yielded an area under the curve
(AUC) of 0.8. At a serum NfL cutoff of 33 pg/mL, the sen-
sitivity improved to 90% and the specificity to 67%. While in
the bvFTD group at baseline, serum NfL still correlated with
the MMSE (r = −0.4445, p = 0.0156), the association with the
CDR and the FTLD-CDR barely failed to be significant. The
correlation of serum NfL with temporal lobe volumes was
more pronounced (r = −0.5226, p = 0.0088) and with frontal
lobe volumes less marked (r = −0.4557, p = 0.0252). For the
Table 3 Analysis of behavioral variant frontotemporal dementia (bvFTD) and Alzheimer disease (AD) subgroups selected
based on CSF biomarker levels (continued)
Aβ42 consistent with non-AD vs AD Aβ42 and tau or p-tau consistent with non-AD vs AD
bvFTD (30) AD (11) bvFTD (31) AD (14)
ROC AUC 0.79 0.77
Sensitivity % 91 93
Specificity % 68 61
Correlation at v2 of serumNfL
with bvFTD
Correlation at v2 of serum
NfL with AD
Correlation at v2 of serumNfL
with bvFTD
Correlation at v2 of serum
NfL with AD
MMSE r = −0.5666 r = −0.4184 r = −0.5735 r = −0.4291
p = 0.0017 p = 0.2003 p = 0.0018 p = 0.1105
CDR-SOB r = 0.4191 r = 0.0838 r = 0.4214 r = 0.5654
p = 0.0236 p = 0.8435 p = 0.0286 p = 0.0554
FTLD-CDR-SOB r = 0.4177 r = 0.1905 r = 0.4192 r = 0.6175
p = 0.0270 p = 0.6514 p = 0.0330 p = 0.0324
Cerebrum r = −0.4353 r = 0.3714 r = −0.4750 r = 0.2143
p = 0.0920 p = 0.4685 p = 0.0736 p = 0.6103
Frontal lobe r = −0.3824 r = 0.7714 r = −0.3964 r = 0.3333
p = 0.1439 p = 0.0724 p = 0.1435 p = 0.4198
Temporal lobe r = −0.6706 r = −0.1429 r = −0.6857 r = 0.1429
p = 0.0045 p = 0.7872 p = 0.0048 p = 0.7358
Hippocampus r = −0.3941 r = −0.1429 r = −0.3857 r = −0.2143
p = 0.1309 p = 0.7872 p = 0.1556 p = 0.6103
Abbreviations: Aβ42 = β-amyloid 1–42; AUC = area under the curve; CDR-SOB = Clinical Dementia Rating scale Sum of Boxes; FTLD = frontotemporal lobar
degeneration; MMSE = Mini-Mental State Examination; NfL = neurofilament light chain; p-tau = phosphorylated tau; pNfH = phosphorylated neurofilament
heavy chain; ROC = receiver operating characteristic; v1 = visit 1; v2 = visit 2.
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AD group, we still did not observe a correlation with func-
tional scores or regional brain volumes. Analysis of follow-up
data yielded similar results, i.e., a better discriminatory power
of serum NfL for discrimination of bvFTD and AD, and
correlation of serum Nfl with global functional scores and
regional brain volumes for bvFTD but not AD.
We then defined subgroups on the basis of both CSF Aβ42
and tau levels and excluded patients with bvFTD with com-
bined decreased Aβ42 and increased tau or p-tau. Accord-
ingly, patients with ADwithout the typical ADCSF biomarker
pattern were excluded from the analyses as well. By ROC
analysis, we calculated an AUC of 0.80 and a sensitivity of 93%
and specificity of 61% at a serum NfL cutoff value of 34.3 pg/
mL. Coefficients for the correlation of serumNfL with clinical
scores and atrophy were very similar to the values calculated
for the cohort defined on the basis of CSF Aβ42 only. For
both subcohorts, we still determined increased serum NfL at
follow-up and the increase was more pronounced for bvFTD
and less marked for AD compared to the entire cohort.
Discussion
Analyzing 74 patients with clinically diagnosed bvFTD at
baseline and at follow-up, we could show that serumNfL level
is increased if compared with controls, patients withMCI, and
patients with AD, increased on average over time, and cor-
related at both examination dates with functional scores and
brain volumes of mainly frontal cortical as well as subcortical
regions well known to be specifically impaired in bvFTD.4,5 In
contrast, the analysis of 26 patients with AD, who had higher
serum NfL levels compared to patients with MCI or controls,
revealed no association of serum NfL and functional or vol-
umetric measures of disease severity.
An increase ofNfL inCSF and association ofCSFNfL levels with
disease severity or progression was observed before in neurode-
generative diseases such as ALS,12,24,30,31 AD,11,32,33 Creutzfeldt-
Jakob disease,34,35 and FTLD.21,33,36–38 Studies investigating
serum NfL showed that levels were strongly associated with NfL
levels in the CSF.16,17,20,39 In the present study, we could show
this for the first time for a large cohort of patients with bvFTD.
We found that serum NfL correlates with the MMSE score
quantifying cognitive impairment, which is in line with a re-
cent article analyzing serum samples of a cohort comprising
74 patients with FTLD, half of whom were diagnosed with
bvFTD.21 Furthermore, in support of the clinical relevance of
NfL for bvFTD, we also found a correlation with the CDR-
SOB, in line with data obtained measuring FTD CSF sam-
ples,36 and with the FTLD-CDR-SOB, a functional score
established to specifically assess disease severity in FTLD
subgroups. The fact that the correlation between serum NfL
and the functional performance persisted at follow-up exam-
ination points to the usefulness of serum NfL as monitoring
marker at different disease stages.
In our bvFTD cohort, serum NfL correlated with brain vol-
umetric measures, which is similar to what could be described
for CSF NfL36 and could have been expected because of the
correlation of NfL levels in CSF and blood. A different study21
of patients with FTD did not find an association with volumes
but with the frontal lobe atrophy rate, which was interpreted
as serum NfL being a marker of severity rather than disease
duration. For our cohort comprising solely patients with
bvFTD, we could not find an association with disease duration
and no correlation with the progression of atrophy. As the
disease duration at baseline in our study relies on the date of
symptom onset reported by the patient or caregiver and
considering the slowly progressive nature of bvFTD, however,
the significance of our results might be limited.
For primary progressive aphasia, where we found a larger in-
crease of serum NfL during progression than for bvFTD in the
present study, we could report on the correlation of serumNfL
concentration change with the atrophy progression rate and
not with brain volumes at the time of serum sampling.20 In
addition, for progressive supranuclear palsy and corticobasal
syndrome, no correlation of white matter lesions with serum
NfL was found.16 Thus there is evidence for differences present
in serum NfL level dynamics and time courses during pro-
gression of the different clinical FTLD subgroups. Whether this
is due to the underlying pathology needs further clinical-to-
neuropathologic studies. As for the vast majority of patients
included in our ongoing multicenter FTLD consortium, the
molecular pathology is not yet assessed; it is a limitation of our
study that analysis of the relation of serum NfL to the un-
derlying molecular pathology could not be carried out. A recent
study described similar CSF NfL levels in definite FTLD with
different molecular pathology,40 which might argue against
a different influence of TDP-43 and tau on NfL level. However,
as in our study, the diagnostic power of the discrimination
between bvFTD and AD improved by excluding patients with
bvFTD with AD-typical CSF Aβ42 concentrations; it might be
that serum NfL is influenced differently by FTLD (TDP-43,
tau) or AD (Aβ42) pathology. Also the fact that the analysis of
our AD group, in contrast to results obtained by others,17 did
not reveal any association of NfL with brain atrophy, although
we observed the reported pattern of degeneration compared to
bvFTD,41,42 could speak for NfL as a pathology-dependent
marker. An alternative interpretation would be that atrophy of
specific brain regions is more reflected in raised serum NfL
levels than atrophy of others. Our data indicate that atrophy in
frontal cortical brain regions, the striatum, and other subcortical
regions contribute more to the CSF and serum NfL level than
degeneration of parietal regions. To clarify these questions,
studies comprising more patients with different patterns of
atrophy and neuropathologically characterized cases have to be
analyzed in comparison. Our study involved a smaller number
of patients with AD than patients with bvFTD.
About 15% of patients with FTD develop ALS in the course of
the disease43 and patients with ALS as well as FTD-ALS are
known to have markedly higher serum NfL levels than
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patients with FTD.21,22 The increase seems to happen just
before or at ALS symptom onset44; hence we suppose that
serum NfL could be useful not only for monitoring bvFTD
severity but also has the potential to detect ALS in bvFTD.
The patients in this study did not develop motor symptoms
over the time course observed, but it would be interesting to
monitor motor symptoms in further follow-up.
We provide evidence for NfL being a blood biomarker
reflecting functional impairment as well as degree of atrophy
of patients with bvFTD at different stages of disease. NfL
might therefore be helpful to monitor effects in upcoming
therapeutic trials targeting neurodegeneration and functional
performance of patients with bvFTD.
Author contributions
All authors made substantial contributions to conception and
design, acquisition of data, or analysis and interpretation of
data. All authors gave final approval of the version to be
submitted and agree to be accountable for all aspects of the
work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated
and resolved. Conception and design of the study: P. Stei-
nacker, M. Otto; sample collection, phenotyping, and data
management: P. Steinacker, S. Anderl-Straub, J. Diehl-
Schmid, E.S. Dipl-Psych, I. Uttner, C.A.F. von Arnim, H.
Barthel, A. Danek, K. Fassbender, K. Fliessbach, H. Foerstl, T.
Grimmer, H-JH, H Jahn, J. Kassubek, J. Kornhuber, B.
Landwehrmeyer, M. Lauer, J.M. Maler, B. Mayer, P. Oeckl, J.
Prudlo, A. Schneider, A.E. Volk, J. Wiltfang, M.L. Schroeter,
A.C. Ludolph, M. Otto; study management and coordination:
P. Steinacker, M. Otto, S. Anderl-Straub, E.S. Dipl-Psych, J.
Diehl-Schmid, A. Danek, A.C. Ludolph; statistical methods
and analysis: P. Steinacker, H.J. Huppertz, B. Mayer; in-
terpretation of results: P. Steinacker, M. Otto; manuscript
writing: P. Steinacker, M. Otto; critical revision of the man-
uscript: P. Steinacker, S. Anderl-Straub, J. Diehl-Schmid, E.S.
Dipl-Psych, I. Uttner, C.A.F. von Arnim, H. Barthel, A. Danek,
K. Fassbender, K. Fliessbach, H. Foerstl, T. Grimmer, H.J.
Huppertz, H Jahn, J. Kassubek, J. Kornhuber, B. Land-
wehrmeyer, M. Lauer, J.M. Maler, B. Mayer, P. Oeckl, J.
Prudlo, A. Schneider, A.E. Volk, J. Wiltfang, M.L. Schroeter,
A.C. Ludolph, M. Otto.
Acknowledgment
The authors thank the patients for participating in this study.
Study funding
The study was supported by grants from the German Federal
Ministry of Education and Research (project: FTLDc
01GI1007A), the EU Joint Programme–Neurodegenerative
Disease Research (JPND) network, PreFrontAls (01ED1512),
the Foundation of the State of Baden-Württemberg (D.3830),
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